The controversies of statin therapy: weighing the evidence.

[1]  C. Rojas-Fernandez,et al.  Is Statin-Associated Cognitive Impairment Clinically Relevant? A Narrative Review and Clinical Recommendations , 2012, The Annals of pharmacotherapy.

[2]  M. Hernán,et al.  Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. , 2012, American journal of epidemiology.

[3]  M. Briel,et al.  Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. , 2012, QJM : monthly journal of the Association of Physicians.

[4]  J. Manson,et al.  Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. , 2012, Archives of internal medicine.

[5]  John Simes,et al.  Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy , 2012, PloS one.

[6]  P. Toth.  Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis , 2012 .

[7]  S. Bonovas,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol , 2011, The Lancet.

[8]  B. Gersh.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2011 .

[9]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[10]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[11]  E. Louis,et al.  Statins and cognitive functioning in the elderly: a population-based study. , 2010, Journal of Alzheimer's disease : JAD.

[12]  V. Wadley,et al.  The Association of Statin Use and Statin Type and Cognitive Performance: Analysis of the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study , 2010, Clinical cardiology.

[13]  N. Sattar,et al.  Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study. , 2009, American journal of epidemiology.

[14]  J Shepherd,et al.  The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.

[15]  Jan P Vandenbroucke,et al.  The HRT controversy: observational studies and RCTs fall in line , 2009, The Lancet.

[16]  J. Mehta,et al.  Effect of Statins on Fasting Plasma Glucose in Diabetic and Nondiabetic Patients , 2009, Journal of Investigative Medicine.

[17]  F. Westwood,et al.  Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy , 2009, The Journal of physiology.

[18]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[19]  P. Macfarlane,et al.  Pravastatin and cognitive function in the elderly. Results of the PROSPER study , 2009, Journal of Neurology.

[20]  T. Trikalinos,et al.  Statins, low-density lipoprotein cholesterol, and risk of cancer. , 2008, Journal of the American College of Cardiology.

[21]  D. Steinberg.  Statin treatment does not cause cancer. , 2008, Journal of the American College of Cardiology.

[22]  D. Redelmeier,et al.  Delirium after elective surgery among elderly patients taking statins , 2008, Canadian Medical Association Journal.

[23]  Jan P Vandenbroucke,et al.  Observational Research, Randomised Trials, and Two Views of Medical Science , 2008, PLoS medicine.

[24]  S. Bonovas,et al.  Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Concato,et al.  Effects of Statin Use on Muscle Strength, Cognition, and Depressive Symptoms in Older Adults , 2007, Journal of the American Geriatrics Society.

[26]  S. Bonovas,et al.  Does pravastatin promote cancer in elderly patients? A meta-analysis , 2007, Canadian Medical Association Journal.

[27]  J. Coombes,et al.  Effect of Atorvastatin on Cognitive Function in Patients from the Lipid Lowering and Onset of Renal Disease (LORD) Trial , 2007, Pharmacotherapy.

[28]  P. Loehrer.  Statins and Cancer Risk: A Meta-analysis , 2007 .

[29]  H. White,et al.  Abstract 1501: Do Low Dose Statins Affect Cognition? Results of the UCSD Statin Study , 2006 .

[30]  A. Folsom,et al.  Lower Myocardial Perfusion Reserve Is Associated With Decreased Regional Left Ventricular Function in Asymptomatic Participants of the Multi-Ethnic Study of Atherosclerosis , 2006, Circulation.

[31]  Lon Cardon,et al.  Lymphotoxin-α Gene and Risk of Myocardial Infarction in 6,928 Cases and 2,712 Controls in the ISIS Case-Control Study , 2006, PLoS genetics.

[32]  B. Schuessler.  What do we know about duloxetine's mode of action? Evidence from animals to humans , 2006, BJOG : an international journal of obstetrics and gynaecology.

[33]  A. Tonkin,et al.  Hormone therapy and cardiovascular disease: a systematic review and meta-analysis , 2006, Journal of Family Planning and Reproductive Health Care.

[34]  N. Baheti,et al.  Effects of atorvastatin on higher functions , 2006, European Journal of Clinical Pharmacology.

[35]  K Yaffe,et al.  Midlife cardiovascular risk factors and risk of dementia in late life , 2005, Neurology.

[36]  J. Flory,et al.  Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. , 2004, The American journal of medicine.

[37]  Ralph I Horwitz,et al.  Beyond randomised versus observational studies , 2004, The Lancet.

[38]  Jan P Vandenbroucke,et al.  When are observational studies as credible as randomised trials? , 2004, The Lancet.

[39]  I. Deary,et al.  Life long changes in cognitive ability are associated with prescribed medications in old age , 2004, International journal of geriatric psychiatry.

[40]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[41]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[42]  P. Doraiswamy,et al.  Statin‐Associated Memory Loss: Analysis of 60 Case Reports and Review of the Literature , 2003, Pharmacotherapy.

[43]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[44]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[45]  R. Stolk,et al.  Atorvastatin, diabetic dyslipidemia, and cognitive functioning. , 2002, Diabetes care.

[46]  V. Hirth,et al.  The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[47]  E. Barrett-Connor,et al.  Serum lipoprotein levels, statin use, and cognitive function in older women. , 2002, Archives of neurology.

[48]  Kenneth Rockwood,et al.  Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. , 2002, Archives of neurology.

[49]  J. Moore,et al.  Effects of lovastatin and pravastatin on cognitive function in military aircrew. , 2001, Aviation, space, and environmental medicine.

[50]  J Tuomilehto,et al.  Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study , 2001, BMJ.

[51]  A. Tonkin,et al.  Benefits of Pravastatin on Cardiovascular Events and Mortality in Older Patients with Coronary Heart Disease Are Equal to or Exceed Those Seen in Younger Patients: Results from the LIPID Trial , 2001, Annals of Internal Medicine.

[52]  P W Macfarlane,et al.  Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.

[53]  Anson,et al.  DIET , LIFESTYLE , AND THE RISK OF TYPE 2 DIABETES MELLITUS IN WOMEN , 2001 .

[54]  H Jick,et al.  Statins and the risk of dementia , 2000, The Lancet.

[55]  J. Concato,et al.  Randomized, controlled trials, observational studies, and the hierarchy of research designs. , 2000, The New England journal of medicine.

[56]  J. Seidell,et al.  Obesity, insulin resistance and diabetes — a worldwide epidemic , 2000, British Journal of Nutrition.

[57]  K. Matthews,et al.  Effects of lovastatin on cognitive function and psychological well-being. , 2000, The American journal of medicine.

[58]  A. Weverling-Rijnsburger,et al.  Total cholesterol and risk of mortality in the oldest old , 1997, The Lancet.

[59]  N. Santanello,et al.  Effect of Pharmacologic Lipid Lowering on Health‐Related Quality of Life in Older Persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study , 1997, Journal of the American Geriatrics Society.

[60]  A. Folsom,et al.  Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. , 1996, The New England journal of medicine.

[61]  D. Reed,et al.  Low serum cholesterol and mortality. Which is the cause and which is the effect? , 1995, Circulation.

[62]  F. Gengo,et al.  Effects of treatment with lovastatin and pravastatin on daytime cognitive performance , 1995, Clinical cardiology.

[63]  C. Lines,et al.  Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. , 1995, British journal of clinical pharmacology.

[64]  Alan C. Wilson,et al.  Central Nervous System Effects of HMG CoA Reductase Inhibitors: Lovastatin and Pravastatin on Sleep and Cognitive Performance in Patients with Hypercholesterolemia , 1994, Journal of clinical pharmacology.

[65]  C. Ashton,et al.  Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. , 1994, British journal of clinical pharmacology.

[66]  J. Dekker,et al.  Inverse association between serum total cholesterol and cancer mortality in Dutch civil servants. , 1993, American journal of epidemiology.

[67]  S. Kritchevsky,et al.  Serum cholesterol and cancer risk: an epidemiologic perspective. , 1992, Annual review of nutrition.

[68]  E. Barrett-Connor,et al.  Cancer mortality and lipid and lipoprotein levels. Lipid Research Clinics Program Mortality Follow-up Study. , 1990, American journal of epidemiology.

[69]  Morris Ba.  The importance of case reports. , 1989, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[70]  A. Reunanen,et al.  Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. , 1988, Journal of clinical epidemiology.

[71]  V. Siskind.  The need for randomization in the study of intended effects. , 1985, Statistics in medicine.

[72]  H. Blackburn,et al.  Serum cholesterol and cancer mortality in the Seven Countries Study. , 1985, American journal of epidemiology.